Posters

Topical bevacizumab may inhibit corneal neovascularization

Poster Details

First Author: M.Mirdehghan IRAN

Co Author(s): A. Kasiri   H. Hedayati   M. Montazeri   S. Emadi   N. Kasiri        

Abstract Details

Purpose:

To evaluate the effect of topical bevacizumab on corneal neovascularization (CNV) in rabbit model following corneal injury.

Setting:

Experimental study at Ahvaz University of Medical Sciences

Methods:

Corneal neovascularization induced by 3 sutures of the cornea in 20 rabbits (20 corneas). Two weeks later all sutures removed and subsequently rabbits were divided randomly into two groups: first group received topical bevacizumab at 10 mg/mL and the second one received only topical normal salin drops as the control group three times a day for two weeks. Photographs of CNV obtained prior medication administration and at 1 and 2 weeks after therapy. The images were analyzed using NIH Imagej 1.49c software.

Results:

The mean percentage of CNV area estimated as 100 % prior to treatment. One week after treatment the mean percentage of neovascularization area in Bevacizumab and Salin group were 75.64±4.32 and 93.33±4.57 respectively. Furthermore at the 2 week after treatment it was 61.45±6.18 and 84.96±5.21 respectively. The neovascularization area in Bevacizumab group regressed in comparison with salin group significantly (P<0.0001).

Conclusions:

Topical administration of Bevacizumab reduces corneal neovascularization in the short term period, therefore it can be applied in corneal neovascularization.

Financial Disclosure:

None